Clayton, Dubilier & Rice (CD&R) and McKesson have agreed to a $5.8bn take-private deal for Option Care Health, the US home and alternate-site infusion provider. CD&R will hold a controlling stake of approximately 51%, while McKesson will invest $1.4bn for a minority interest of around 49%. The transaction includes $2.87bn in committed equity and up to $3.15bn in debt financing.
Option Care will continue under its existing management team, with a framework in place for McKesson to eventually acquire CD&R’s stake subject to regulatory approvals. The deal is expected to close in the first half of 2027, after which Option Care’s shares will be delisted from Nasdaq. The company provides infusion therapy across all 50 states and employs over 8,000 people, including more than 5,000 clinicians.
The merger agreement includes a $146m break fee and a $292m reverse termination fee. Shareholder approval and antitrust clearance under the Hart-Scott-Rodino Act are required.
Source: PE Insights · Summarized by HeadlinesBriefing